[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100570859":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":33,"locations":41,"responsibleParty":62,"collaborators":64,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":24,"eligibilityCriteria":72,"healthyVolunteers":69,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":24,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":91,"whyStopped":24,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"University of Minnesota","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CKD patients group 1","EXPERIMENTAL","assigned to Low P Diet (LP) then High P Diet (HP),",[13],"Other: LP then HP",{"label":15,"type":10,"description":16,"interventionNames":17},"CKD patients group 2","assigned to HP, then LP.",[18],"Other: HP then LP",[20,25],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"LP then HP","Cross-over order of LP then HP diet. Each cross-over phase will be 19 days and consist of a 7-day outpatient, controlled diet period, followed by a 5-day inpatient, controlled diet, balance, and kinetic study period, followed by a second 7-day outpatient, controlled diet period.",[9],null,{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"HP then LP","Cross-over order of HP then LP diet. Each cross-over phase will be 19 days and consist of a 7-day outpatient, controlled diet period, followed by a 5-day inpatient, controlled diet, balance, and kinetic study period, followed by a second 7-day outpatient, controlled diet period.",[15],[30],{"name":31,"affiliation":5,"role":32},"Kathleen Hill Gallant, PhD","PRINCIPAL_INVESTIGATOR",[34,38],{"name":31,"role":35,"phone":36,"phoneExt":24,"email":37},"CONTACT","612-625-5285","hillkm@umn.edu",{"name":39,"role":35,"phone":24,"phoneExt":24,"email":40},"Study Coordinator","KidneyNutrition@umn.edu",[42],{"facility":43,"status":24,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Indiana University School of Medicine","Indianapolis","Indiana","46202","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-86.15804,39.76838,{"lat":53,"lon":52},[56,60],{"name":57,"role":35,"phone":58,"phoneExt":24,"email":59},"Mary Balmes-Fenwick","317-948-7772","mbalmes@iu.edu",{"name":61,"role":32,"phone":24,"phoneExt":24,"email":24},"Sharon M Moe, MD",{"type":63,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[65],{"name":66,"class":6},"Indiana University","100570859","effects-of-dietary-phosphorus-on-phosphorus-and-calcium-whole-body-balance-and-kinetics-in-moderate-ckd-100570859",false,"NCT06712719","Effects of Dietary Phosphorus on Phosphorus and Calcium Whole-Body Balance and Kinetics in Moderate CKD","Inclusion Criteria:\n\n* Men or women, ages 30-75 years old, any race or ethnicity\n* Moderate CKD, defined by KDIGO as eGFR category 3b (30-44 mL\u002Fmin) or 4 (16-29 mL\u002Fmin) with albuminuria categories A1-A3\n* Serum intact parathyroid hormone above assay normal limit\n* Female subjects must be postmenopausal (\\>12 months since last menstrual period), surgically sterile, or confirmed not pregnant by pregnancy test\n* Must be on stable doses of medications (except those noted in exclusion criteria) for at least 4 weeks prior to the study\n* Willing to discontinue supplements (e.g., vitamin D, calcium, multivitamin\u002Fminerals, or others) upon enrollment until completion of the study\n* Adequate vitamin D status defined as serum 25D \\> 20 ng\u002FmL based on National Academy of Medicine (then Institute of Medicine) criteria.\n\nExclusion Criteria:\n\n* Plans to initiate dialysis within 6 months\n* Hypercalcemia defined as corrected serum calcium \\>9.8 mg\u002FdL within past 3 months\n* Hyperkalemia defined as serum potassium \\>5.5 mg\u002FdL within past 3 months\n* Hyperphosphatemia defined as serum phosphate \\>5.5 mg\u002FdL within past 3 months\n* Intestinal disease that alters absorption or normal intestinal function including celiac disease, small bowel resection, bariatric surgery, or chronic diarrhea\u002Fmalabsorption\n* Serious, uncontrolled underlying systemic disease including diabetes, lupus, hypertension in the opinion of their physician\n* Pregnant or breastfeeding\n* Prescribed and taken a phosphate binder medication, calcitriol, vitamin D analogs, calcimimetics, PTH analogues, and other medications that may alter Ca and P metabolism within past 4 weeks\n* Non-English speaking","ALL","30 Years","75 Years",{"count":77,"type":78},14,"ESTIMATED","INTERVENTIONAL",[81],"NA","The aim of the study is to look at the effects of dietary phosphorus on phosphorous and calcium whole-body balance and kinetics in moderate chronic kidney disease (CKD). N = 14 enrolled subjects will be randomly assigned to a cross-over order of (A) Low P Diet, High P Diet. Each cross-over phase will be 19 days and consist of a 7-day outpatient, controlled diet period, followed by a 5- day inpatient, controlled diet, balance, and kinetic study period, followed by a second 7-day outpatient, controlled diet period.",[84],"CKD",[86,87,88,89,90],"phosphorus","phosphate","balance","diet","calcium","NOT_YET_RECRUITING","2026-05-18",{"date":94,"type":95},"2026-05-20","ACTUAL",{"date":97,"type":78},"2026-06",{"date":99,"type":78},"2027-05",{"name":5,"class":6},1]